- Conditions
- OTC Deficiency, Ornithine Transcarbamylase Deficiency, OTCD
- Interventions
- ARCT-810
- Biological
- Lead sponsor
- Arcturus Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Chevy Chase, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Covid19
- Interventions
- COVI-AMG, Placebo
- Biological · Drug
- Lead sponsor
- Sorrento Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 4
- States / cities
- Garden Grove, California • Bradenton, Florida • Miami, Florida + 1 more
- Conditions
- Healthy Volunteers
- Interventions
- [18F]MNI-1054
- Drug
- Lead sponsor
- Invicro
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Pleural Effusion Associated With Pulmonary Infection, Pleural Effusion Disorder, Pleural Effusions
- Interventions
- Pleural Saline Irrigation
- Combination Product
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Congenital Muscular Dystrophy
- Interventions
- Omigapil
- Drug
- Lead sponsor
- Santhera Pharmaceuticals
- Industry
- Eligibility
- 5 Years to 16 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Essential Tremor
- Interventions
- Sodium Oxybate, Placebo
- Drug · Other
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Bingham Farms, Michigan
- Conditions
- Influenza, SARS-CoV-2
- Interventions
- mRNA-1083 Composition 1 Dose A Lot A, mRNA-1083 Composition 1 Dose A Lot B, mRNA-1083 Composition 1 Dose B, mRNA-1083 Composition 1 Dose C, mRNA-1083 Composition 2 Dose A, mRNA-1083 Composition 2 Dose B, mRNA-1083 Composition 3 Dose A, mRNA-1083 Composition 3 Dose B, Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza Vaccine, Investigational COVID-19 Vaccine Lot A, Investigational COVID-19 Vaccine Lot B
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 1,320 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • San Diego, California • Stockbridge, Georgia + 13 more
- Conditions
- ADHD
- Interventions
- Placebo, 200mg SPN-812, 400mg SPN-812
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 10
- States / cities
- Long Beach, California • Lauderhill, Florida • Orlando, Florida + 7 more
- Conditions
- Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
- Interventions
- Inclacumab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 18
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Orange, California + 7 more
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed, Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Las Vegas, Nevada • New York, New York + 1 more
- Conditions
- Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- Interventions
- TAK-007, Chemotherapy Agents
- Biological · Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2038
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more
- Conditions
- Plasmodium Falciparum
- Interventions
- NMRC-M3V-Ad-PfCA, NMRC-MV-Ad-PfC, NMRC-M3V-Ad-PfCA
- Biological
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Influenza, Virus Diseases
- Interventions
- Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Kidney Disease With High Proteinuria
- Interventions
- Zibotentan/Dapagliflozin, Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 1,835 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 64
- States / cities
- Huntsville, Alabama • Sun City West, Arizona • Bakersfield, California + 55 more
- Conditions
- Glabellar Frown Lines
- Interventions
- Botulinum Toxins, Type A, Placebos
- Biological
- Lead sponsor
- Revance Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 9
- States / cities
- Encinitas, California • Los Angeles, California • Washington D.C., District of Columbia + 6 more
- Conditions
- Plaque Psoriasis
- Interventions
- TAK-279
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,099 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 62 more
- Conditions
- Healthy
- Interventions
- PF-06412562 3mg BID, PF-06412562 15mg BID, Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 77 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 3
- States / cities
- Arcadia, California • Glendale, California
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy
- Interventions
- IgPro20 (low dose), Placebo, IgPro10, IgPro20 (high dose)
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
- Conditions
- Obesity and Overweight
- Interventions
- (Part C) MET097, (Part C) Placebo
- Biological
- Lead sponsor
- Metsera, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Anaheim, California • Cypress, California • Overland Park, Kansas
- Conditions
- Actinic Keratosis
- Interventions
- AM001 Cream, 7.5%, Vehicle Cream
- Drug
- Lead sponsor
- AmDerma
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- High Point, North Carolina
- Conditions
- Influenza
- Interventions
- FluMist
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 5 Years to 49 Years
- Enrollment
- 345 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2005
- U.S. locations
- 11
- States / cities
- Miami, Florida • Chicago, Illinois • Bardstown, Kentucky + 8 more
- Conditions
- Influenza, Healthy
- Interventions
- Monovalent Influenza Vaccine, Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 301 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 3
- States / cities
- South Miami, Florida • Stockbridge, Georgia • Portland, Oregon
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Lithium Carbonate, Riluzole, placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 19 more
- Conditions
- Staphylococcus Aureus
- Interventions
- Aurexis® (tefibazumab)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 7 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia